The DOI matches its Crossref record; 157 of the 159 references it cites were found in a registry or an index.
TIM3 comes of age as an inhibitory receptor
Open accessAbstract
T cell immunoglobulin and mucin domain-containing protein 3 (TIM3), a member of the TIM family, was originally identified as a receptor expressed on interferon-γ-producing CD4+ and CD8+ T cells. Initial data indicated that TIM3 functioned as a 'co-inhibitory' or 'checkpoint' receptor, but due to the lack of a definable inhibitory signalling motif, it was also suggested that TIM3 might act as a co-stimulatory receptor. Recent studies have shown that TIM3 is part of a module that contains multiple co-inhibitory receptors (checkpoint receptors), which are co-expressed and co-regulated on dysfunctional or 'exhausted' T cells in chronic viral infections and cancer. Furthermore, co-blockade of TIM3 and programmed cell death 1 (PD1) can result in tumour regression in preclinical models and can improve anticancer T cell responses in patients with advanced cancers. Here, we highlight the developments in understanding TIM3 biology, including novel ligand identification and the discovery of loss-of-function mutations associated with human disease. In addition, we summarize emerging data from human clinical trials showing that TIM3 indeed acts as a 'checkpoint' receptor and that inhibition of TIM3 enhances the antitumour effect of PD1 blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nevertheless, tyrosine kinase FYN and human leukocyte antigen B (HLA‐B)‐associated transcript 3 (BAT3) were suggested to inhibit the cytoplasmic tail of TIM‐3 signaling [307, 308, 309].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [307]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the latter of which encodes the checkpoint molecule TIM3, one of the most promising new therapeutic approaches in cancer 32 that was recently described in a GWAS as an AD risk gene 2 .”
From APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints (2023) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
Self-citationMiller, B. C., Sen, D. R., Al Abosy, R., Bi, K., Virkud, Y. V., LaFleur, M. W., Yates, K. B., Lako, A., Felt, K., Naik, G. S., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0312-6 · Cited by 2,087
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Self-citationDefining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Im, S. J., Hashimoto, M., Gerner, M. Y., Lee, J., Kissick, H. T., Burger, M. C., Shan, Q., Hale, J. S., Lee, J., Nasti, T. H., et al. (2016) · Nature · doi:10.1038/nature19330 · Cited by 2,070
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057
Self-citationDefining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Research works printed but not linked: 2
- Weiss, G. J. et al. A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in patients (pts) with advanced solid tumors. J. Immunother. Cancer 5, 86 (2017).
- Davar, D. et al. A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in combination with TSR-042 (anti-PD-1) in patients with colorectal cancer and post-PD-1 NSCLC and melanoma. J. Immunother. Cancer 6, 115 (2018).
Cited by
Sorted by citations
Items 701–800 of 963
Gray, S., & Ottensmeier, C. H. H. (2023) · Cancers · doi:10.3390/cancers15194797 · Cited by 4
Chen, X., Tang, R., Zha, J., Zeng, L., Zhou, L., Liu, Z., Yang, D., Zeng, M., Zhu, X., Chen, A., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1365226 · Cited by 3
Xu, S., Yang, L., He, Y., Chen, Y., Qin, F., & Hu, W. (2025) · Discover Oncology · doi:10.1007/s12672-025-02673-2 · Cited by 3
Nguyen, M. T. T., Nguyen, V. V. T., Le, H., Nguyen, D. V., Nguyen, M., Hermiston, M. L., Bui, C., & Loh, A. H. P. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29292 · Cited by 3
Li, J., & Wang, J. (2022) · Medical Science Monitor · doi:10.12659/msm.935326 · Cited by 3
An anti-tumor coup: TIM3 ablation activates the immune arsenal
Görgülü, K., Kabacaoğlu, D., & Algül, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00757-3 · Cited by 3
Koya, T., Niida, Y., Togi, M., Yoshida, K., Sakamoto, T., Ura, H., Togi, S., Kato, T., Yamada, S., Sugiyama, H., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012177 · Cited by 3
Engelmann, R., Jaekel, N., Jotschke, S., Ludwig‐Kraus, B., Kraus, F. B., Kumari, N., Schulze, S., Hecker, M., Zahn, C., Al‐Ali, H. K., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009054 · Cited by 4
Haham, N., Zveik, O., Rechtman, A., Brill, L., & Vaknin‐Dembinsky, A. (2024) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2024.578289 · Cited by 2
Kalkusova, K., Táborská, P., Stakheev, D., Rataj, M., Smite, S., Darras, E., Albo, J., Bartůňková, J., Vannucci, L. E., & Smrž, D. (2024) · Journal of Immunology Research · doi:10.1155/2024/5537948 · Cited by 2
A novel loss of function mutation in the HAVCR2 gene in a patient diagnosed with Hodgkin’s lymphoma
Erdem, Ş., Yilmaz, E. A., Özcan, A., Canatan, A. N., Bişgin, A., Doğan, M. E., Karakükçü, M., Ünal, E., & Eken, A. (2025) · Immunologic Research · doi:10.1007/s12026-025-09618-5 · Cited by 2
Yu, T. C.-Y., Tsui, Y., Zhang, V. X., Ma, H., & Ng, I. O. (2025) · Cancer Heterogeneity and Plasticity · doi:10.47248/chp2502020006 · Cited by 2
Gao, S., Liu, T., & Liu, Q. (2025) · International Urology and Nephrology · doi:10.1007/s11255-025-04527-w · Cited by 2
BET Protein Inhibition Relieves MDSC-Mediated Immune Suppression in Chronic Lymphocytic Leukemia
Drengler, E. M., Smith, A. L., Skupa, S. A., Schmitz, E. G., Mohamed, E. T., & El-Gamal, D. (2025) · Hemato · doi:10.3390/hemato6020014 · Cited by 2
Mutational accumulation drives pathway dysregulation to predict glioma patient survival
Wan, M., Zhuang, C.-P., Li, W., Yan, R., Chen, W., Cheng, J., Yue, C., Chen, L., & Quan, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-12346-3 · Cited by 2
Yang, H., Shen, T., Qi, Z., Yang, Z., Zhang, M., Jiang, J., Sun, Z. R., & Lu, C. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110638 · Cited by 2
Immune checkpoints in hepatocellular carcinoma and the challenges of therapeutic resistance
Tao, X., & Yang, X. (2025) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2025.2542137 · Cited by 3
Chkolnaia, Z., Reinisch, W., & Uzzan, M. (2025) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaf160 · Cited by 2
Unraveling the Role of Azobenzene‐Based Photoswitchable Lipids in Controlling Innate Immune Response
Delova, A., Makhloutah, A., Bernhard, Y., Pasc, A., & Monari, A. (2025) · Chemistry - A European Journal · doi:10.1002/chem.202501824 · Cited by 2
Li, J., Zhou, Y., Song, Y., Dai, G., Li, X., Sun, Y., Wang, J., Wei, R., Li, F., & Xi, L. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08231-6 · Cited by 2
Soluble TIM-3 and galectin-9 predict survival in gastric and gastroesophageal junction cancer
Digomann, D., Reiche, C., Stammberger, A., Willms, T., Rudek, L. S., Grabenkamp, A., Klimová, A., Kölbel, J., Merboth, F., Natusch, L., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113871 · Cited by 2
Therapeutic opportunities in EBV-positive gastric cancer subtypes
Al-Sattar, H., Owen, R. P., Jaafari, A. M., Saha, A., Ayyappan, K., Ghose, A., Boussios, S., & Adeleke, S. M. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251396619 · Cited by 2
TIM-3 Inhibitor Development: Overcoming Immune Evasion in Cancer Therapy
Wang, L., Shen, H., Jiang, B., Wang, X., Yang, P., & Sun, C. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02693 · Cited by 2
Han, X., Guan, L., Huang, L., Fan, Y., Guo, F., Liang, D., Guan, X., & Chen, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1705438 · Cited by 2
Song, G., Wang, L., Zhao, G., Tan, S., Liu, X., & Li, X. (2026) · Precision Radiation Oncology · doi:10.1002/pro6.70047 · Cited by 2
Meyaard, L., & van der Vlist, M. (2026) · Annual Review of Immunology · doi:10.1146/annurev-immunol-083024-025659 · Cited by 3
Zhang, B., Muhetarijiang, M., Sun, X., Wu, Y., Justin, R., Li, Z., Chen, T., Zhou, D., & Hu, X. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm43846 · Cited by 2
Fu, C., Ma, T., Clausen, B. E., Mellman, I., & Jiang, A. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2518080123 · Cited by 2
Lei, K., Tian, J., Zhang, L., Gong, Z., Liu, W., Wan, Z., Wang, Y., Li, R., Dong, B., & Wang, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1784450 · Cited by 2
The Signaling Networks of TIM-3, TGF-β, and STING in Glioblastoma
Ahmady, F., Carnie, B. M. H., Anderson, G. E. C., Achari, E., Sharma, A., Achuthan, A. A., Kannourakis, G., & Luwor, R. B. (2026) · Cells · doi:10.3390/cells15110991 · Cited by 2
Ratka, Z., Gamian, A., & Woźniak, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114923 · Cited by 2
KIM-1 and beyond: emerging biomarkers for adjuvant immunotherapy in clear cell renal cell carcinoma
Rosellini, M., Danielli, L., Bibbò, A., Musio, M., Ricci, C., Piazza, P., Santoni, M., Mollica, V., & Massari, F. (2026) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2026.2687507 · Cited by 2
Xu, C., Wang, S.-Y., Nie, M., Yang, K., Huang, X., Qu, S., Chen, H. H., Shen, L., Huang, J.-M., Zhang, F., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-26-0347 · Cited by 2
Rethinking biomarker strategy in gastric cancer immunotherapy: from tumor to host
Ismaili, N. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1847526 · Cited by 2
Feasibility of hepatocellular carcinoma treatment based on the tumor microenvironment
Wang, H., Shi, F., Zheng, S., Zhao, M., Pan, Z., Xiong, L., & Zheng, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.896662 · Cited by 2
Advances in the expression and function of Fyn in different human tumors
Liu, C., Li, S., & Tang, Y. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03167-9 · Cited by 2
Chen, P., Li, Z., & Li, N. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30337 · Cited by 3
Research progress of immunotherapy for advanced head and neck cancer
Sun, A., Xing, Z., Lv, R., Niu, P., Zhao, B. L., Ma, S., & Li, H. (2024) · Medical Oncology · doi:10.1007/s12032-024-02375-9 · Cited by 2
Discovery of new myositis genetic associations through leveraging other immune-mediated diseases
Reales, G., Amos, C. I., Benvéniste, O., Chinoy, H., Bleecker, J. D., Paepe, B. D., Doria, A., Gregersen, P. K., Lamb, J. A., Limaye, V. S., et al. (2024) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2024.100336 · Cited by 2
TIM3 in COVID-19; A potential hallmark?
Zamani, M. R., & Šácha, P. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e40386 · Cited by 2
Li, S., Pan, Y., Ye, R., Wang, Y., & Li, L. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113717 · Cited by 2
Biomarkers of Immune Dysregulation and What They Tell Us
Nguyen, T. H., & Chandrakasan, S. (2025) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2025.01.003 · Cited by 2
Emerging new immune checkpoint inhibitors in solid tumor immunotherapy
Poorkhani, A., Tajaldini, M., Ahmadi, F., Tahmasebifar, A., Azadehrah, M., Azadehrah, M., Ghamoushiramandi, A., Amiri, R. S., & Khori, V. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04131-w · Cited by 4
Wu, C. (2025) · Discover Oncology · doi:10.1007/s12672-025-02944-y · Cited by 2
Wedel, J., Kochupurakkal, N. M., Kong, S. W., Bose, S., Lee, J.-W., Maslyar, M., Alsairafi, B., MacLeod, K., Liu, K., Zhang, H., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci172218 · Cited by 2
Exploring BenzylethoxyAryl Urea Scaffolds for Multitarget Immunomodulation Therapies
Gil-Edo, R., Hernández-Ribelles, G., Royo, S., Thawait, N., Serrels, A., Cardá, M., & Falomir, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108582 · Cited by 2
[Developments in Immunotherapy for Advanced Non-small Cell Lung Cancer].
Li, H., & Wang, J. (2021) · PubMed Central · doi:10.3779/j.issn.1009-3419.2021.102.06 · Cited by 2
Gao, Y., Lu, Y., Fan, X.-Z., Wang, Y.-H., Tian, J., Saed, Y. A., Li, R., & Zhou, X. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108971 · Cited by 2
Carty, S. A., Murga‐Zamalloa, C., & Wilcox, R. A. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.04.007 · Cited by 2
Zhao, Y., Qu, Y., Duan, M., Hao, C., & Yao, W. (2023) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2023.115087 · Cited by 2
Oudah, S. M., Hamzah, I. H., Matti, B. F., & Alkasir, R. (2024) · Al-Mustansiriyah Journal of Sciences · doi:10.23851/mjs.v35i1.1418 · Cited by 2
Perspectives on the Role of T Cell Negative Immune Checkpoint Receptors in Health and Disease
Fujita, T., Clements, D. M., Premeaux, T. A., & Ndhlovu, L. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-33946-3_6 · Cited by 2
Desmirean, M., Rauch, S., Jurj, A. M., Paşca, S., Iluta, S., Teodorescu, P., Berce, C., Zimța, A., Turcas, C., Țigu, A. B., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113412 · Cited by 2
Wu, S., Du, X., Lou, G., Yu, S., Lai, K., Qi, J., Ni, S., Chen, Z. J., & Chen, F. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07841-1 · Cited by 1
Kilicaslan, U. K., Aru, B., Aksu, S. A., Aker, F., Demirel, G. Y., & Gürleyik, G. (2024) · Surgical Oncology · doi:10.1016/j.suronc.2024.102037 · Cited by 1
A Comprehensive Review on Cancer Immunotherapy in Veterinary Medicine
Saiyad, S., Bhanderi, B. B., KORINGA, P. G., Mathakiya, R. A., & Nimavat, V. R. (2024) · International Journal of Biochemistry Research & Review · doi:10.9734/ijbcrr/2024/v33i5875 · Cited by 1
Ferencz, B., Török, K., Pipek, O., Fillinger, J., Csende, K., Lantos, A., Černeková, R., Mitták, M., Škarda, J., Delongová, P., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03704-7 · Cited by 1
Вячеславович, Н. К., Perik-Zavodskii, R., Shevchenko, J. A., & Sennikov, S. V. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47070550 · Cited by 1
METTL7A is a potential biomarker for the diagnosis and prognosis of acute myeloid leukemia
Xie, Z., Tan, Y., Zhang, T., Zhang, M.-M., Wang, M., & Li, J. (2025) · Hematology · doi:10.1080/16078454.2025.2535882 · Cited by 1
Antibody treatments for digestive cancers: Past, present, and future
Dadi, I., Mazard, T., Schmitt, L.-M., Chastel, T., Turtoï, A., Poul, M., & Pattingre, S. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152369 · Cited by 1
Novel Radiofluorinated Nanobody PET Tracer for Preclinical Studies of TIM3 Expression
Zheng, D., Huang, Y., Li, C., Lu, Y., Xie, Z., Liang, Y., Ren, Q., & Meng, X. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00839 · Cited by 1
Palmitoylation modulates antitumor immunity
Tang, F. R., Xu, J., Zhang, Q., Chen, X., Wang, X., Xu, Y.-D., & Li, Z. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11084-z · Cited by 1
Liu, H., Li, H., Li, S., Shang, Y., Tang, S., & Pang, Y. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s540343 · Cited by 1
Yang, C., Gao, M., Zhang, X., Yu, H., & Deng, C. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03774-4 · Cited by 2
MacLean, F., Zemek, R. M., Tsegaye, A. T., Graham, J. B., Swarts, J. L., Vick, S. C., Potchen, N. B., Talavera, I. C., Warrier, L., Dubrulle, J., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.197491 · Cited by 1
Chen, S., Wang, X., Xu, Y., Zeng, W., He, G., & Wen, X. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00367-3 · Cited by 1
Brydon, J., Krejčíř, R., Grima, M., Zavadil-Kokas, F., Kuncova, Z., Sousan, S., Pflughaupt, R. L., Thomson, J. R., Davies, P., Senior, E., et al. (2025) · Analytical Biochemistry · doi:10.1016/j.ab.2025.116033 · Cited by 1
Wang, J., Wang, Q., Zhou, J., Zhou, L., Ren, X., & Wei, F. (2025) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiaf180 · Cited by 1
Pramanik, S., Thaker, M., Inoue, N., Kim, P., Kutzner, A., Manavalan, A., Pramanik, G., & Heese, K. (2026) · Discover Oncology · doi:10.1007/s12672-025-03876-3 · Cited by 1
Demšar, A., Geršak, K., Gazić, B., Blagus, T., Goričar, K., Jezernik, G., Dolzan, & Kuhar, C. G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052431 · Cited by 1
Pharmacologic progress in higher-risk MDS: an uphill battle
Mina, A. A., & Zeidan, A. M. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2644384 · Cited by 1
Tumor immunogenicity shapes CNS immune niches and CD8⁺ T cell fate in glioblastoma
Asalla, S., Ahumada, O. S., Krull, J. E., Wang, Y., Patel, D. N., Gupta, V., Wieland, A., Giglio, P., Ma, Q., Tedeschi, A., et al. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03754-x · Cited by 1
Large-scale proteomic analyses before depression diagnosis reveal novel pathophysiological insights
Cheng, B., Cheng, S., Pan, C., Wei, W., Feng, J., Qi, X., Zhao, B., Wen, Y., & Zhang, F. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03540-4 · Cited by 1
Gupta, P., Valdebenito, S., Kumar, G., Chakrapani, P., Oberai, S., Dang, M., Katayama, H., Wang, L., Eugenín, E. A., & Bhat, K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1733688 · Cited by 1
TIM-3 in AML: pathogenic roles and therapeutic targetability
Zhong, L., & Samarkhazan, H. S. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02133-3 · Cited by 2
Viscidi, R. P., Huang, J., Li, Y., Severance, E. G., & Xiao, J. (2026) · Scientific Reports · doi:10.1038/s41598-026-49283-8 · Cited by 1
Tang, L., Wang, H., Chen, J., Zhang, Y., Huang, Y., & Li, X. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.152623 · Cited by 1
Novel approaches for separating graft-versus-leukemia effects from graft-versus-host disease
Hasegawa, Y., Teshima, T., & Hashimoto, D. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1838922 · Cited by 1
Akbari, A. M., Bourbour, S., Seyedmehdi, M. S., Shiari, S., Rustamzadeh, A., Seif, F., & Farivar, S. (2026) · Biologics · doi:10.2147/btt.s603545 · Cited by 1
Javadi, P., & Azadi, A. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103452 · Cited by 1
Zhang, W., Yoshiji, S., SLADEK, R. M., Dupuis, J., & Lu, T. (2026) · Genomics Proteomics & Bioinformatics · doi:10.1093/gpbjnl/qzag087 · Cited by 2
Xiang, M., Liu, S., Xiao, D., & Tao, Y. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02810-5 · Cited by 1
Crosslinking-mediated activation of the FcεRI: Does it need antigen for success?
Huber, M., & Capellmann, S. (2022) · Biocell · doi:10.32604/biocell.2022.018513 · Cited by 1
MicroRNAs Targeting Tumor Microenvironment and Immune Modulation
Roy, S., & Prasad, D. (2022) · Springer eBooks · doi:10.1007/978-981-16-9186-7_6 · Cited by 1
Tawanwongsri, W., & Thongsroy, J. (2022) · Case Reports in Dermatology · doi:10.1159/000527530 · Cited by 1
New Approaches Targeting Immuno-oncology and Tumor Microenvironment
Zhu, D., & He, F. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_89 · Cited by 1
Zhang, Y., Zhang, W., Yuan, Q., Hong, W., Yin, P., Shen, T., Fang, L., Jiang, J., Shi, F., & Chen, W. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1145676 · Cited by 1
Lin, J., Ran, Y., Wu, T., Wang, Z., Zhao, J., & Tian, Y. (2023) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000497 · Cited by 1
Welch, B. M., Manso, B. A., Gwin, K. A., Lothert, P. K., Parikh, S. A., Kay, N. E., & Medina, K. L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1302038 · Cited by 1
Jiang, G., Neuber, B., Hückelhoven‐Krauss, A., Höpken, U. E., Ding, Y., Sedloev, D. N., Wang, L., Reichman, A., Eberhardt, F., Wermke, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031394 · Cited by 1
Zentsová, I., Klocperk, A., Bloomfield, M., Kubešová, H., Malcová, H., Cebecauerová, D., Horváth, R., Šedivá, A., & Paračková, Z. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.110170 · Cited by 1
Caetano, D. G., Toledo, T. S., de Lima, A. C. S., Giacoia-Gripp, C. B. W., de Almeida, D. V., de Lima, S. M. B., Azevedo, A. D. S., Morata, M., Grinsztejn, B. G. J., Cardoso, S. W., et al. (2024) · Vaccines · doi:10.3390/vaccines12060578 · Cited by 2
Mahanti, M., Gummesson, S., Sundin, A., Leffler, H., Zetterberg, F. R., & Nilsson, U. J. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117989 · Cited by 1
Asl, A. S., Davari, M., Ghorbani, A., Seddighi, N., Arabi, K., & Saburi, E. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113790 · Cited by 1
Inhibitory and Activating Natural Killer Receptors in Humans: A Historical Overview
Cantoni, C., Falco, M., Vitale, M., Sivori, S., Pende, D., Mingari, M. C., & Moretta, L. (2025) · Springer eBooks · doi:10.1007/978-3-662-68816-8_26-1 · Cited by 1
Wu, J.-J., Guo, S., Lv, L.-L., Zhai, J., Shen, Y., Chen, C., & Qu, Q. (2024) · PubMed Central · doi:10.3779/j.issn.1009-3419.2024.102.46 · Cited by 1
Pallathadka, H., Khaleel, A. Q., Hjazi, A. M., Kumar, A., Aloraibi, F., Kadhum, W. R., Pramanik, A., Hamzah, H. F., Mohammed, S. K., & Mustafa, Y. F. (2025) · Human Immunology · doi:10.1016/j.humimm.2025.111264 · Cited by 1
Li, Y., Sun, Q., Yang, Z., LuoMin, Yang, W., Song, Z., Liu, K., Li, H., Gao, W., Wu, Q., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.040 · Cited by 1
Proteolysis-targeting chimeras (PROTACs) as novel biotechnology for cancer therapy
Fuchs, O. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90042-3.15001-7 · Cited by 1
Aging Interacts with Tumor Biology to Produce Major Changes in the Immune Tumor MicroenvironmentPreprint
Erbe, R., Wang, Z., Zaidi, N., Topper, M. J., Baylin, S. B., Jaffee, E. M., Easwaran, H., & Fertig, E. J. (2020) · SSRN Electronic Journal · doi:10.1101/2020.06.08.140764 · Cited by 2
Metadata
- Authors
- Wolf, Y., Anderson, A. C., & Kuchroo, V. K.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Kuchroo, Vijay K.
- Venue
- Nature Reviews Immunology
- Published
- 2019-11-01
- Volume
- 20
- Issue
- 3
- Pages
- 173-185
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- PMC
- PMC7327798
- OpenAlex
- W2985205513
- Cited by
- 959
- References
- 159
- Citations by year
- 2026: 98 · 2025: 140 · 2024: 191 · 2023: 160 · 2022: 183 · 2021: 142 · 2020: 44
- FWCI
- 8.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (R01CA187975)
- National Institute of Allergy and Infectious Diseases (P01AI073748, P01AI056299, P01AI039671)
- National Institute of Neurological Disorders and Stroke (R01NS045937)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- TIM-3, inhibitory receptors, co-inhibitory receptors, immune checkpoint, T cell exhaustion, loss-of-function mutations, antitumor immunity, chronic viral infection, cancer immunotherapy
- MeSH terms
- Hepatitis A Virus Cellular Receptor 2, Animals, Clinical Trials as Topic, Humans, Signal Transduction, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
